Table 3

Disease activity at baseline and after 6 months of methotrexate monotherapy

PsA
N=980
RA
N=1794
Baseline6 monthsBaseline6 months
DAS28-CRP, mean (SD)4.1 (1.1)2.8 (1.1)4.5 (1.2)2.6 (1.1)
 Available %80638673
DAS28, mean (SD)4.2 (1.3)2.9 (1.2)4.8 (1.3)2.7 (1.3)
 Available %76588468
Patient-reported pain, mean (SD)53 (23)32 (25)52 (25)26 (24)
 Available %86678875
Patient-reported global health, mean (SD)50 (24)33 (25)50 (25)27 (24)
 Available %87678976
CRP, median (IQR)7.0 (13.8)4.0 (5.0)9.0 (18)4.0 (4.4)
 Available %95709878
Swollen 28-joint count, mean (SD)4.1 (4.2)1.4 (2.5)6.8 (5.2)1.5 (2.6)
 Available %93709778
Tender 28-joint count, mean (SD)5.3 (5.1)2.2 (3.5)7.0 (5.6)2.0 (3.5)
 Available %93709778
Evaluator’s assessment of disease activity, Likert scale
 Remission, N (%)5 (1)162 (25)10 (1)452 (33)
 Low, N (%)179 (20)349 (53)265 (16)639 (47)
 Moderate, N (%)567 (63)131 (20)890 (54)226 (17)
 High, N (%)139 (15)17 (3)462 (28)34 (3)
 Maximal, N (%)7 (1)031 (2)0
 Available %92679275
  • CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; PsA, psoriatic arthritis; RA, rheumatoid arthritis.